Apogee Therapeutics (APGE) Assets (2022 - 2026)

Apogee Therapeutics (APGE) has 5 years of Assets data on file, last reported at $1.3 billion in Q1 2026.

• Assets for Q1 2026 came in at $1.3 billion, up 81.14% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.3 billion (up 81.14% YoY), and the FY2025 annual result was $937.1 million, up 24.3% from the prior year.
• Assets improved to $1.3 billion in Q1 2026 per APGE's latest filing, from $937.1 million in the prior quarter.
• Over five years, Assets peaked at $1.3 billion in Q1 2026 and troughed at $130.7 million in Q2 2023.
• A 5-year average of $653.4 million and a median of $714.2 million in 2025 frame the typical range for Assets.
• The sharpest annual moves came in 2024 and 2025: Assets soared 512.75% in 2024, then decreased 19.34% in 2025.
• A 5-year view of Assets shows it stood at $152.1 million in 2022, then surged by 163.99% to $401.4 million in 2023, then surged by 87.83% to $754.0 million in 2024, then gained by 24.3% to $937.1 million in 2025, then jumped by 38.04% to $1.3 billion in 2026.
• Business Quant data shows APGE's Assets at $1.3 billion in Q1 2026, $937.1 million in Q4 2025, and $626.2 million in Q3 2025.